Related Experiment Videos
[Distribution of Streptococcus pneumoniae serotypes in Nantes Hospital (1969-1978) (author's transl)]
Abstract:
Between 1969 and 1978 at the CHR of Nantes we isolated Streptococcus pneumoniae from 815 swabs taken from 591 patients and which provided 595 different strains. Serotyping of all the strains was carried out using the capsular reaction test. The prevalence of the different serovars varied according to the year and the type of swab. No resistant strains to benzylpenicillin or ampicillin were observed. There was significant resistance to sulphonamides and tetracycline : 24,3 and 29,6% respectively. The American vaccine containing the greatest number of serovars was effective for only 69,8% of the strains isolated in Nantes.
Insights
This study analyzed Streptococcus pneumoniae strains from 1969-1978, finding significant resistance to sulfonamides and tetracycline. The available pneumococcal vaccine demonstrated limited effectiveness against circulating serovars.
Area of Science:
- Microbiology
- Epidemiology
- Infectious Diseases
Context:
- Analysis of Streptococcus pneumoniae (pneumococcus) strains isolated between 1969 and 1978.
- Data collected from 591 patients at the CHR of Nantes.
- Involved serotyping of 595 distinct pneumococcal strains using the capsular reaction test.
Purpose:
- To investigate the prevalence of different pneumococcal serovars over a decade.
- To assess antibiotic resistance patterns in isolated strains.
- To evaluate the efficacy of the then-available American pneumococcal vaccine.
Summary:
- Serovar prevalence varied annually and by sample type.
- No resistance to benzylpenicillin or ampicillin was detected.
- Significant resistance observed for sulfonamides (24.3%) and tetracycline (29.6%).
- The American vaccine covered only 69.8% of the isolated strains.
Impact:
- Highlights the dynamic nature of pneumococcal serovar distribution.
- Identifies key antibiotic resistance trends in Streptococcus pneumoniae.
- Underscores limitations of early pneumococcal vaccines, informing future vaccine development and public health strategies.